The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL – Results From the Phase-II STORM Trial

User: Guest

Document type:: Zeitschriftenaufsatz
Author(s):: Witzens-Harig, Mathias; Viardot, Andreas; Keller, Ulrich; Wosniok, Julia; Deuster, Oliver; Klemmer, Jennifer; Geueke, Anne-Marie; Meißner, Julia; Ho, Anthony D.; Atta, Johannes; Marks, Reinhard; La Rosée, Paul; Buske, Christian; Dreyling, Martin H.; Hess, Georg
Title:: The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL – Results From the Phase-II STORM Trial
Journal title:: HemaSphere
Year:: 2021
Journal volume:: 5
Journal issue:: 10
Pages contribution:: e636
Fulltext / DOI:: doi:10.1097/hs9.0000000000000636
Publisher:: Ovid Technologies (Wolters Kluwer Health)
E-ISSN:: 2572-9241
Date of publication:: 23.09.2021
BibTeX

Occurrences: